$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

$celz Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000147793224006991 Filed on November 08, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$0.00	$6.000K
YoY Change		-100.0%	-89.09%
Cost Of Revenue		$0.00	$2.400K
YoY Change		-100.0%	-85.0%
Gross Profit		$0.00	$3.600K
YoY Change		-100.0%	-90.77%
Gross Profit Margin			60.0%
Selling, General & Admin		$498.6K	$531.0K
YoY Change		-6.11%	-34.07%
% of Gross Profit			14751.17%
Research & Development		$581.8K	$992.7K
YoY Change		-41.39%	329.86%
% of Gross Profit			27575.61%
Depreciation & Amortization		$29.27K	$20.00K
YoY Change		46.35%	-13.12%
% of Gross Profit			555.56%
Operating Expenses		$1.110M	$1.547M
YoY Change		-28.26%	46.0%
Operating Profit		-$1.110M	-$1.543M
YoY Change		-28.09%	51.23%
Interest Expense		$69.54K	$90.00K
YoY Change		-22.73%
% of Operating Profit
Other Income/Expense, Net		$69.54K	$89.23K
YoY Change		-22.07%	134.31%
Pretax Income		-$1.040M	-$1.454M
YoY Change		-28.46%	48.01%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings		-$1.040M	-$1.454M
YoY Change		-28.46%	48.01%
Net Earnings / Revenue			-24232.53%
Basic Earnings Per Share
Diluted Earnings Per Share		-$0.75	-$1.02
COMMON SHARES
Basic Shares Outstanding	1.748M shares	1.338M shares	1.431M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.260M	$4.510M
YoY Change	38.81%	-73.42%
Cash & Equivalents	$6.260M	$4.507M
Short-Term Investments	$0.00
Other Short-Term Assets	$67.61K	$7.530M
YoY Change	-99.1%	49.96%
Inventory	$3.394K	$7.794K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$6.331M	$12.04M
YoY Change	-47.43%	-45.27%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.280K	$0.00
YoY Change		-100.0%
Total Long-Term Assets	$556.5K	$469.8K
YoY Change	18.45%	1.71%
TOTAL ASSETS
Total Short-Term Assets	$6.331M	$12.04M
Total Long-Term Assets	$556.5K	$469.8K
Total Assets	$6.888M	$12.51M
YoY Change	-44.96%	-44.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$273.8K	$367.0K
YoY Change	-25.41%	11.96%
Accrued Expenses	$42.92K	$39.92K
YoY Change	7.52%	-27.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$330.9K	$421.2K
YoY Change	-21.43%	6.1%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$330.9K	$421.2K
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$330.9K	$421.2K
YoY Change	-21.43%	6.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$62.74M	-$57.42M
YoY Change	9.26%	20.64%
Common Stock	$1.431K	$1.431K
YoY Change	0.0%	-89.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$191.8K
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.557M	$12.09M
YoY Change
Total Liabilities & Shareholders Equity	$6.888M	$12.51M
YoY Change	-44.96%	-44.31%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$1.040M	-$1.454M
YoY Change	-28.46%	48.01%
Depreciation, Depletion And Amortization	$29.27K	$20.00K
YoY Change	46.35%	-13.12%
Cash From Operating Activities	-$985.6K	-$1.300M
YoY Change	-24.19%	48.86%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$200.0K	$1.820M
YoY Change	-110.99%	-136.25%
Cash From Investing Activities	-$200.0K	$1.820M
YoY Change	-110.99%	-136.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-25.45K	0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-985.6K	-1.300M
Cash From Investing Activities	-200.0K	1.820M
Cash From Financing Activities	-25.45K	0.000
Net Change In Cash	-1.211M	520.0K
YoY Change	-332.89%	-108.82%
FREE CASH FLOW
Cash From Operating Activities	-$985.6K	-$1.300M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1431	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	330908	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	371394	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	3394	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	1431	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62737839	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	277246	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	6331440	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	10270898	usd
CY2024Q3	us-gaap	Other Assets OtherAssets	3281	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	3281	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	553198	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	441011	usd
CY2024Q3	us-gaap	Assets Assets	6887919	usd
CY2023Q4	us-gaap	Assets Assets	10715190	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	317280	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39920	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69711749	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59098432	usd
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	101250	shares
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	6557011	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3466867	usd
CY2024Q3	us-gaap	Investments Investments	0	usd
CY2023Q4	us-gaap	Investments Investments	6520191	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	67608	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	273794	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	42920	usd
CY2024Q3	celz	Due To Related Party Current DueToRelatedPartyCurrent	14194	usd
CY2024Q3	us-gaap	Liabilities Liabilities	330908	usd
CY2023Q4	us-gaap	Liabilities Liabilities	371394	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1431126	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1431126	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1329876	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1373626	shares
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69739235	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	57500	shares
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	445916	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	270952	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10343796	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6887919	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10715190	usd
CY2024Q3	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	250000	usd
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10
	celz	Number Of Authorized Shares Reduction Description NumberOfAuthorizedSharesReductionDescription	50 million to five million
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	100000	usd
CY2020Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	100000	usd
	celz	Payments In The Event Of Commercialization Of Technology PaymentsInTheEventOfCommercializationOfTechnology	300000	usd
CY2017Q2	celz	Payments Upon Completion Of Irb Clinical Trial PaymentsUponCompletionOfIrbClinicalTrial	200000	usd
CY2017Q2	celz	Description For The Consecutive Trading Days DescriptionForTheConsecutiveTradingDays	In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles
CY2020Q4	celz	Performance Obligation And Payment PerformanceObligationAndPayment	50000	usd
CY2020Q4	celz	Performance Obligation And Payment PerformanceObligationAndPayment	50000	usd
CY2020Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	300000	usd
CY2021Q3	celz	Performance Obligation And Payment PerformanceObligationAndPayment	40000	usd
CY2021Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	300000	usd
	us-gaap	Unrecorded Unconditional Purchase Obligation Description UnrecordedUnconditionalPurchaseObligationDescription	The remaining portion of the $300,000 obligation was paid in cash in 2020.
CY2023Q3	celz	Remaining Portion Of Obligation Paid In Cash RemainingPortionOfObligationPaidInCash	100000	usd
CY2024Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	300000	usd
	celz	Amortization Expenses AmortizationExpenses	34455	usd
CY2024Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	75979	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	46000	usd
CY2023Q4	celz	Licensing Agreements LicensingAgreements	860000	usd
CY2023Q4	celz	Accumulated Amortization Of Licensing Agreements AccumulatedAmortizationOfLicensingAgreements	-418989	usd
	celz	Addition Of New Assets AdditionOfNewAssets	200000	usd
	celz	Accumulated Amortization Addition Of New Assets AccumulatedAmortizationAdditionOfNewAssets	0	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
	celz	Accumulated Amortization AccumulatedAmortization	-87813	usd
CY2024Q3	celz	Licensing Agreements LicensingAgreements	1060000	usd
CY2024Q3	celz	Accumulated Amortization Of Licensing Agreements AccumulatedAmortizationOfLicensingAgreements	-506802	usd
CY2021Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	300000	usd
CY2022Q4	celz	Cost Of Purchased Equipment CostOfPurchasedEquipment	5000000	usd
CY2023Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	3000000.0	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0081	pure
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.9295	pure
CY2024Q3	us-gaap	Share Price SharePrice	18.30
	dei	Entity Central Index Key EntityCentralIndexKey	0001187953
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
	celz	Amortization Expenses AmortizationExpenses	34455	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-53500
	dei	Entity Registrant Name EntityRegistrantName	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0622284
	dei	Entity Address Address Line1 EntityAddressAddressLine1	211 E Osborn Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Phoenix
	dei	Entity Address State Or Province EntityAddressStateOrProvince	AZ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	85012
	dei	City Area Code CityAreaCode	480
	dei	Local Phone Number LocalPhoneNumber	399-2822
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	CELZ
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1748428	shares
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6260438	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	6594	usd
CY2023Q4	celz	Due To Related Party Current DueToRelatedPartyCurrent	14194	usd
CY2024Q3	us-gaap	Revenues Revenues	0	usd
CY2023Q3	us-gaap	Revenues Revenues	6000	usd
	us-gaap	Revenues Revenues	8000	usd
	us-gaap	Revenues Revenues	6000	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	2400	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3200	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2400	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	0	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	3600	usd
	us-gaap	Gross Profit GrossProfit	4800	usd
	us-gaap	Gross Profit GrossProfit	3600	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	581796	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	992722	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1928937	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1621231	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	498607	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	531042	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1846177	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2161599	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	29271	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	23021	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	87813	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	69063	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	1109674	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1546785	usd
	us-gaap	Operating Expenses OperatingExpenses	3862927	usd
	us-gaap	Operating Expenses OperatingExpenses	3851893	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1109674	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1543185	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3858127	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3848293	usd
CY2024Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	69539	usd
CY2023Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	89233	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	218720	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	240293	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	69539	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	89233	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	218720	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	240293	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1040135	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1453952	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3639407	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3608000	usd
CY2024Q3	celz	Ncome Tax Expense Benefit ncomeTaxExpenseBenefit	0	usd
CY2023Q3	celz	Ncome Tax Expense Benefit ncomeTaxExpenseBenefit	0	usd
	celz	Ncome Tax Expense Benefit ncomeTaxExpenseBenefit	0	usd
	celz	Ncome Tax Expense Benefit ncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1040135	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1453952	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3639407	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3608000	usd
CY2024Q3	celz	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.75
CY2023Q3	celz	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-1.02
	celz	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-2.59
	celz	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-2.55
CY2024Q3	celz	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	1392284	shares
CY2023Q3	celz	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	1431426	shares
	celz	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	1406259	shares
	celz	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	1416319	shares
	us-gaap	Profit Loss ProfitLoss	-3639407	usd
	us-gaap	Profit Loss ProfitLoss	-3608000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	27486	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	27486	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	87813	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	69063	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3200	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2400	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	209638	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	276642	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-43486	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2900493	usd
	celz	Accrued Expenses AccruedExpenses	3000	usd
	celz	Accrued Expenses AccruedExpenses	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3351756	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6132902	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	6437188	usd
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	6520191	usd
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	9048459	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	200000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	100000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6320191	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2511271	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	174964	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	191780	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	100	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-174864	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-191780	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2793571	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3813411	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3466867	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8320519	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6260438	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4507108	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10343796	usd
	celz	Purchase Of Treasury Stock PurchaseOfTreasuryStock	-174964	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	27486	usd
	celz	Issuance Of Series B Preferred Stock Amount IssuanceOfSeriesBPreferredStockAmount	100	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3639407	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	6557011	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	7613434	usd
CY2024Q3	celz	Purchase Of Treasury Stock PurchaseOfTreasuryStock	-25450	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	9162	usd
CY2024Q3	celz	Issuance Of Series B Preferred Stock Amount IssuanceOfSeriesBPreferredStockAmount	0	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1040135	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	6557011	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	15864674	usd
	celz	Round Up Shares Issued In Reverse Stock Split Amount RoundUpSharesIssuedInReverseStockSplitAmount	0	usd
	celz	Purchase Of Treasury Stock PurchaseOfTreasuryStock	-191780	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	27486	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3608000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	12092380	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	13728950	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	9162	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1453952	usd
CY2023Q3	celz	Purchase Of Treasury Stock PurchaseOfTreasuryStock	-191780	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	12092380	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Use of Estimates –</em></strong>The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024Q3	us-gaap	Deferred Revenue DeferredRevenue	43000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	40000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Concentration Risks</strong></em> – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at four financial institutions. As of September 30, 2024, the Company’s balance exceeded the limit at three institutions. </p>
	celz	Round Up Shares Issued In Reverse Stock Split Shares RoundUpSharesIssuedInReverseStockSplitShares	23502	shares
CY2016Q1	celz	Number Of Share Exchange NumberOfShareExchange	43112	shares
CY2024Q3	celz	Initial Payment Amount InitialPaymentAmount	100000	usd
CY2017Q2	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date
CY2017Q2	celz	Initial Payments To Acquire Intangible Assets InitialPaymentsToAcquireIntangibleAssets	100000	usd
CY2024Q3	celz	Additional Cmh Payment Amount AdditionalCMHPaymentAmount	50000	usd
	celz	Obligation Due Through Issuance Of Common Stocks ObligationDueThroughIssuanceOfCommonStocks	300000	usd
	celz	Payment For Clinical Trial Amount PaymentForClinicalTrialAmount	200000	usd
	celz	Payment For Clinical Trial Amount PaymentForClinicalTrialAmount	200000	usd
CY2024Q2	celz	Purchase Price In Cash PurchasePriceInCash	100	usd
CY2024Q2	celz	Number Of Voting Rights NumberOfVotingRights	100000000	integer
CY2024Q3	celz	Outstanding Share Of Series B Preferred Stock Redeemed Amount OutstandingShareOfSeriesBPreferredStockRedeemedAmount	100	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure

Files In Submission

Name	View Source	Status
0001477932-24-006991-index-headers.html	Edgar Link	pending
0001477932-24-006991-index.html	Edgar Link	pending
0001477932-24-006991.txt	Edgar Link	pending
0001477932-24-006991-xbrl.zip	Edgar Link	pending
celz-20240930.xsd	Edgar Link	pending
celz_10q.htm	Edgar Link	pending
celz_10qimg2.jpg	Edgar Link	pending
celz_ex311.htm	Edgar Link	pending
celz_ex312.htm	Edgar Link	pending
celz_ex321.htm	Edgar Link	pending
celz_ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
celz-20240930_cal.xml	Edgar Link	unprocessable
celz-20240930_def.xml	Edgar Link	unprocessable
celz-20240930_lab.xml	Edgar Link	unprocessable
celz-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
celz_10q_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2024 Q4 Form 10-Q Financial Statement

#000147793224006991 Filed on November 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2024 Q4 Form 10-Q Financial Statement

#000147793224006991 Filed on November 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz